Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität, München, Germany.
Leukemia. 2013 Oct;27(10):2016-22. doi: 10.1038/leu.2013.171. Epub 2013 Jun 11.
The introduction of tyrosine kinase inhibitors (TKI) in the treatment of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) has revolutionized the outcome, but the prognosis of the disease is still based on prognostic systems that were developed in the era of conventional chemotherapy and interferon (IFN)-alfa. A new prognostic score including only two variables, spleen size and basophils, was developed for the prediction of complete cytogenetic response (CCyR) and progression-free survival (PFS). The score was based on a large series of patients who were enrolled in prospective multicenter studies of first-line imatinib treatment. The prognostic value of the EUTOS (European Treatment and Outcome Study for CML) score has now been tested in an independent, multicenter, multinational series of 1288 patients who were treated first-line with imatinib outside prospective studies. It was found that also in these patients, the EUTOS prognostic score was predictive for CCyR, PFS and overall survival (OS). In addition, the prognostic value of the score was reported to be significant in seven of the eight other independent studies of almost 2000 patients that were performed in Europe, the Americas and Asia. The EUTOS risk score is a valid tool for the prediction of the therapeutic effects of TKI, particularly imatinib.
酪氨酸激酶抑制剂（TKI）在治疗费城染色体阳性（Ph+）慢性髓性白血病（CML）中的应用彻底改变了治疗效果，但疾病的预后仍然基于在传统化疗和干扰素（IFN）-α时代开发的预后系统。一个新的预后评分系统仅包含两个变量，脾脏大小和嗜碱性粒细胞，用于预测完全细胞遗传学缓解（CCyR）和无进展生存（PFS）。该评分系统基于一项大型前瞻性多中心伊马替尼一线治疗研究的患者系列。EUTOS（欧洲 CML 治疗和结果研究）评分的预后价值现已在 1288 例接受伊马替尼一线治疗的前瞻性研究外的独立、多中心、跨国患者系列中得到验证。结果发现，在这些患者中，EUTOS 预后评分也可预测 CCyR、PFS 和总生存（OS）。此外，该评分的预后价值在欧洲、美洲和亚洲进行的其他 7 项独立的近 2000 例患者研究中也有报道，这些研究的结果也具有显著意义。EUTOS 风险评分是 TKI，特别是伊马替尼治疗效果预测的有效工具。
